Document is current

Article History

Received: 2 December 2024

Revised: 20 January 2025

Accepted: 22 January 2025

First Online: 15 February 2025

Declarations

:

: Maximilian J Mair has received research support from Bristol-Myers Squibb and travel support from Pierre Fabre. Franziska Eckert has received travel support and honoraria for lectures or advisory board participation from Dr. Sennewald Medizintechnik and Servier. Matthias Preusser has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: AbbVie, AstraZeneca, Bayer, BMJ Journals, Bristol-Myers Squibb, CMC Contrast, Daiichi Sankyo, Gan & Lee Pharmaceuticals, Gerson Lehrman Group, GlaxoSmithKline, Lilly, Medahead, MedMedia, Merck Sharp & Dohme, Mundipharma, Novartis, Roche, Sanofi, Servier, Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to his institution: AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Merck Sharp & Dohme, Novocure, Roche. Anna Sophie Berghoff has research support from Daiichi Sankyo, Roche and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa, Seagen, Alexion, Servier as well as travel support from Roche, Amgen and AbbVie. All other authors declare that they have no conflict of interest related to the present study.

: This study was approved by the Ethics Committees of the Medical University of Vienna (protocol no. 1166/2019, 2290/2020) and the Kepler University Hospital Linz (protocol no. 1274/2019) and was performed according to the Declaration of Helsinki and its amendments as well as according to institutional and national guidelines. Due to the retrospective nature of the study, no written informed consent was needed according to applicable law and institutional and national guidelines.

: Not applicable.